查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020126

避孕藥具市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Contraceptive Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 151 Pages | 商品交期: 請詢問到貨日

價格

避孕藥具市場的成長要素

受人們對計劃生育和生殖健康意識不斷提高的推動，全球避孕藥具市場正經歷穩定成長。預計到2025年，該市場規模將達到212.1億美元，2026年將成長至228.1億美元，到2034年將達到447.4億美元，預測期內複合年成長率為8.79%。

由於較高的意識層級、有利的報銷政策以及大型製藥企業的存在，預計到 2025 年，北美將以 38.52% 的市場佔有率主導全球市場。

市場概覽

避孕藥具廣泛用於預防意外懷孕和管理生殖健康。這些藥物，包括口服避孕藥、注射和貼劑，在人口控制和預防性性行為感染方面發揮著至關重要的作用。

隨著人們對人口快速成長的擔憂日益加劇，尤其是在中低收入國家，世界各國政府和醫療機構正在加強避孕宣傳。宣傳活動和教育計畫顯著提高了全球避孕普及率。

新冠疫情的影響

新冠疫情對避孕藥具市場造成了負面影響，供應鏈中斷和計劃生育服務取得受限是主要原因。許多國家的生殖健康服務受到影響。

然而，隨著 2020 年至 2021 年間封鎖限制的放鬆和計劃生育項目的恢復，市場逐漸復甦，全球對避孕藥具的需求也隨之恢復。

市場趨勢

向現代避孕方法過渡

影響市場的主要趨勢之一是從傳統避孕方式轉向口服避孕藥、注射和荷爾蒙貼片等現代方法。與傳統方法相比，這些現代方法被認為具有更高的有效性和便利性。

現代避孕方法的日益普及，尤其是在職業女性和都市區中，極大地促進了市場成長。

市場促進因素

公眾意識的提高和政府舉措

政府計畫、非政府組織和製藥公司都在積極推廣避孕意識提升。拜耳公司和曼金製藥等公司所進行的宣傳活動在擴大避孕解決方案的可及性方面發揮了至關重要的作用。

優惠的還款措施

在已開發地區，特別是北美和歐洲，支持性的報銷機制發揮了積極作用。保障免費或補貼取得避孕藥具的政策顯著提高了產品的使用率。

意外懷孕率上升

全球意外懷孕人數的不斷增加是推動避孕藥需求成長的另一個重要因素，尤其是在新興經濟體。

市場限制因素

儘管預計市場將保持強勁成長，但以下因素可能會限制市場擴張：

  • 副作用包括噁心、頭痛和體重增加。
  • 增加長期健康併發症的風險
  • 發展中地區的社會偏見和意識不足
  • 避孕套和子宮內避孕器（IUD）等替代品的可用性

這些因素可能會限制它在某些地區的普及。

細分分析

副產品

口服避孕藥目前佔市場主導地位，預計到2026年將佔91.39%的市場。其主導地位主要歸功於口服避孕藥的易用性、可及性和消費者對其的強烈偏好。注射避孕藥由於其成本效益，預計也將顯著成長。

透過分銷管道

預計到2026年，零售藥局將佔最大的市場佔有率，達到45.47%，這主要得益於非處方避孕藥供應量的增加。線上管道因其便利性和折扣優惠而迅速崛起。

區域趨勢

  • 北美：在高品牌知名度和誘人激勵措施的推動下，預計到 2025 年市場規模將達到 81.7 億美元，到 2026 年將達到 87 億美元。
  • 歐洲：預計到 2025 年將達到 52.9 億美元，這得益於其強大的醫療保健基礎設施。
  • 亞太地區：預計到 2025 年將達到 42.9 億美元，這主要得益於政府舉措以及印度和中國等國家日益增強的意識。
  • 拉丁美洲、中東和非洲：由於宣傳宣傳活動的增加和醫療保健服務的改善，這些地區呈現穩定成長的態勢。

主要行業趨勢

  • 2023 年：FDA核准了第一款非處方口服避孕藥（歐必樂）。
  • 2023年：Lupin公司生產的非專利避孕藥已獲得FDA核准。
  • 2022年：拜耳獲得資金用於非荷爾蒙避孕藥的研究。
  • 2022年：Mithra Pharmaceuticals在澳洲推出了「NEXTSTELLIS」。

儘管副作用和社會障礙等挑戰依然存在，但持續的產品創新和生殖健康服務可近性的提高有望維持長期成長。未來十年，該市場預計將在全球人口控制和女性健康促進方面發揮關鍵作用。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年總合國家/地區總和生育率
  • 2025年主要國家口服避孕藥使用率
  • 主要國家注射避孕藥的普及率（2025 年）
  • 管道分析，主要企業
  • 監管趨勢－避孕藥具，主要地區
  • 重大工業發展－併購、新產品發布
  • 新冠疫情對市場的影響

第5章：2021-2034年全球避孕藥具市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品分類。
    • 口服
      • 複方避孕藥
      • 僅含黃體素的避孕藥
    • 注射藥物
    • 修補
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 診所
    • 線上管道
    • 公共管道和非政府組織
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美避孕藥具市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲避孕藥具市場分析、洞察與預測（2021-2034年）

  • 國家
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區避孕藥具市場分析、洞察與預測（2021-2034年）

  • 國家
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章：拉丁美洲避孕藥具市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲

第10章：中東和非洲避孕藥具市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Piramal Enterprises Ltd.
    • Agile Therapeutics
    • Johnson & Johnson Services, Inc.
    • AbbVie Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Amneal Pharmaceuticals LLC
    • Bayer AG
Product Code: FBI100063

Growth Factors of contraceptive drugs Market

The global contraceptive drugs market is experiencing steady growth driven by rising awareness of family planning and reproductive health. The market was valued at USD 21.21 billion in 2025 and is projected to grow to USD 22.81 billion in 2026, reaching USD 44.74 billion by 2034, registering a CAGR of 8.79% during the forecast period.

North America dominated the global market with a 38.52% share in 2025, supported by strong awareness levels, favorable reimbursement policies, and the presence of major pharmaceutical players.

Market Overview

Contraceptive drugs are widely used to prevent unintended pregnancies and manage reproductive health. These drugs, including oral pills, injectables, and patches, play a critical role in population control and reducing the spread of sexually transmitted diseases.

Growing concerns about rapid population growth, especially in low- and middle-income countries, have led governments and healthcare organizations to increase awareness regarding contraception methods. Campaigns and educational initiatives are significantly improving adoption rates worldwide.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the contraceptive drugs market due to supply chain disruptions and reduced access to family planning services. Many countries experienced interruptions in reproductive healthcare services.

However, the market recovered gradually during 2020-2021 as lockdown restrictions eased and family planning programs resumed, restoring demand for contraceptive drugs globally.

Market Trends

Shift Toward Modern Contraceptive Methods

A major trend shaping the market is the transition from traditional to modern contraceptive methods such as oral pills, injectables, and hormonal patches. These methods offer higher effectiveness and convenience compared to conventional options.

The increasing adoption of modern contraception, particularly among working women and urban populations, is significantly boosting market growth.

Market Drivers

Rising Awareness and Government Initiatives

Government programs, NGOs, and pharmaceutical companies are actively promoting contraception awareness. Campaigns such as those by Bayer AG and Mankind Pharma have played a key role in expanding access to contraceptive solutions.

Favorable Reimbursement Policies

Developed regions, particularly North America and Europe, benefit from supportive reimbursement frameworks. Policies ensuring free or subsidized contraceptive access have significantly increased product adoption.

Increasing Unintended Pregnancies

The rising number of unintended pregnancies globally is another critical factor driving demand for contraceptive drugs, especially in emerging economies.

Market Restraints

Despite strong growth, several factors may limit market expansion:

  • Side effects such as nausea, headaches, and weight gain
  • Increased risk of long-term health complications
  • Social stigma and lack of awareness in developing regions
  • Availability of alternative methods such as condoms and intrauterine devices (IUDs)

These factors may restrict widespread adoption in certain regions.

Segmentation Analysis

By Product

The oral contraceptives segment dominated the market, accounting for 91.39% share in 2026. This dominance is due to ease of use, widespread availability, and strong consumer preference. Injectable products are expected to witness significant growth due to their cost-effectiveness.

By Distribution Channel

The retail pharmacy segment held the largest share of 45.47% in 2026, driven by the growing availability of over-the-counter contraceptive drugs. Online channels are emerging rapidly due to convenience and discounts.

Regional Insights

  • North America: Valued at USD 8.17 billion in 2025 and USD 8.70 billion in 2026, driven by high awareness and favorable policies.
  • Europe: Accounted for USD 5.29 billion in 2025, supported by strong healthcare infrastructure.
  • Asia Pacific: Reached USD 4.29 billion in 2025, fueled by government initiatives and rising awareness in countries such as India and China.
  • Latin America & Middle East & Africa: Showing steady growth due to increasing awareness campaigns and improving healthcare access.

Competitive Landscape

The market is fragmented with several global and regional players focusing on innovation and partnerships. Key companies include:

  • Pfizer Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries
  • Viatris Inc.
  • Johnson & Johnson

These companies are investing in product innovation, generic drug development, and strategic collaborations to strengthen their market presence.

Key Industry Developments

  • 2023: FDA approved the first non-prescription oral contraceptive (Opill).
  • 2023: Lupin received FDA approval for generic contraceptive tablets.
  • 2022: Bayer received funding for non-hormonal contraceptive research.
  • 2022: Mithra Pharmaceuticals launched NEXTSTELLIS in Australia.

Conclusion

The contraceptive drugs market is poised for steady expansion, growing from USD 21.21 billion in 2025 to USD 44.74 billion by 2034. Increasing awareness, supportive government initiatives, and the shift toward modern contraceptive methods are key growth drivers.

While challenges such as side effects and social barriers persist, continuous product innovation and improved access to reproductive healthcare will sustain long-term growth. The market is expected to play a vital role in global population control and women's health advancement over the coming decade.

Segmentation

By Product

  • Oral
    • Combined Contraceptives
    • Progestin-only Pills
  • Injectable
  • Patches

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online Channels
  • Public Channels & NGOs
  • Others

By Region

  • North America (By Product, By Distribution Channel, and By Country)
    • U.S. (By Product)
    • Canada (By Product)
  • Europe (By Product, By Distribution Channel, and By Country/Sub-region)
    • U.K. (By Product)
    • Germany (By Product)
    • France (By Product)
    • Italy (By Product)
    • Spain (By Product)
    • Scandinavia (By Product)
    • Rest of Europe (By Product)
  • Asia Pacific (By Product, By Distribution Channel, and By Country/Sub-region)
    • Japan (By Product)
    • China (By Product)
    • India (By Product)
    • Australia (By Product)
    • Southeast Asia (By Product)
    • Rest of Asia Pacific (By Product)
  • Latin America (By Product, By Distribution Channel, and By Country/Sub-region)
    • Brazil (By Product)
    • Mexico (By Product)
    • Rest of Latin America (By Product)
  • Middle East & Africa (By Product, By Distribution Channel, and By Country/Sub-region)
    • GCC (By Product)
    • South Africa (By Product)
    • Rest of Middle East & Africa (By Product)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Total Fertility Rate, By Key Countries/ Region, 2025
  • 4.2. Penetration of Oral Contraceptive Pills, Key Countries, 2025
  • 4.3. Penetration of Injectable Contraceptives, Key Countries, 2025
  • 4.4. Pipeline Analysis, Key Players
  • 4.5. Regulatory Scenario - Contraceptive Drugs, Key Regions
  • 4.6. Key Industry Developments- Mergers, Acquisitions, New Product Launches
  • 4.7. Impact of COVID-19 on the Market

5. Global Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Oral
      • 5.1.1.1. Combined Contraceptives
      • 5.1.1.2. Progestin-only Pills
    • 5.1.2. Injectable
    • 5.1.3. Patches
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacy
    • 5.2.2. Retail Pharmacy
    • 5.2.3. Clinics
    • 5.2.4. Online Channel
    • 5.2.5. Public Channel & NGOs
    • 5.2.6. Others
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Oral
      • 6.1.1.1. Combined Contraceptives
      • 6.1.1.2. Progestin-only Pills
    • 6.1.2. Injectable
    • 6.1.3. Patches
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacy
    • 6.2.2. Retail Pharmacy
    • 6.2.3. Clinics
    • 6.2.4. Online Channel
    • 6.2.5. Public Channel & NGOs
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
      • 6.3.1.1. By Product
    • 6.3.2. Canada
      • 6.3.2.1. By Product

7. Europe Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Oral
      • 7.1.1.1. Combined Contraceptives
      • 7.1.1.2. Progestin-only Pills
    • 7.1.2. Injectable
    • 7.1.3. Patches
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacy
    • 7.2.2. Retail Pharmacy
    • 7.2.3. Clinics
    • 7.2.4. Online Channel
    • 7.2.5. Public Channel & NGOs
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.3.1. Germany
      • 7.3.1.1. By Product
    • 7.3.2. U.K.
      • 7.3.2.1. By Product
    • 7.3.3. France
      • 7.3.3.1. By Product
    • 7.3.4. Italy
      • 7.3.4.1. By Product
    • 7.3.5. Spain
      • 7.3.5.1. By Product
    • 7.3.6. Scandinavia
      • 7.3.6.1. By Product
    • 7.3.7. Rest of Europe
      • 7.3.7.1. By Product

8. Asia Pacific Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Oral
      • 8.1.1.1. Combined Contraceptives
      • 8.1.1.2. Progestin-only Pills
    • 8.1.2. Injectable
    • 8.1.3. Patches
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacy
    • 8.2.2. Retail Pharmacy
    • 8.2.3. Clinics
    • 8.2.4. Online Channel
    • 8.2.5. Public Channel & NGOs
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.3.1. India
      • 8.3.1.1. By Product
    • 8.3.2. China
      • 8.3.2.1. By Product
    • 8.3.3. Japan
      • 8.3.3.1. By Product
    • 8.3.4. Australia
      • 8.3.4.1. By Product
    • 8.3.5. Southeast Asia
      • 8.3.5.1. By Product
    • 8.3.6. Rest of Asia Pacific
      • 8.3.6.1. By Product

9. Latin America Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Oral
      • 9.1.1.1. Combined Contraceptives
      • 9.1.1.2. Progestin-only Pills
    • 9.1.2. Injectable
    • 9.1.3. Patches
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacy
    • 9.2.2. Retail Pharmacy
    • 9.2.3. Clinics
    • 9.2.4. Online Channel
    • 9.2.5. Public Channel & NGOs
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.3.1. Brazil
      • 9.3.1.1. By Product
    • 9.3.2. Mexico
      • 9.3.2.1. By Product
    • 9.3.3. Rest of Latin America
      • 9.3.3.1. By Product

10. Middle East & Africa Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Oral
      • 10.1.1.1. Combined Contraceptives
      • 10.1.1.2. Progestin-only Pills
    • 10.1.2. Injectable
    • 10.1.3. Patches
  • 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.2.1. Hospital Pharmacy
    • 10.2.2. Retail Pharmacy
    • 10.2.3. Clinics
    • 10.2.4. Online Channel
    • 10.2.5. Public Channel & NGOs
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.3.1. GCC
      • 10.3.1.1. By Product
    • 10.3.2. South Africa
      • 10.3.2.1. By Product
    • 10.3.3. Rest of Middle East & Africa
      • 10.3.3.1. By Product

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Piramal Enterprises Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Agile Therapeutics
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. AbbVie Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Pfizer Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Teva Pharmaceutical Industries Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Viatris Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Amneal Pharmaceuticals LLC
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. Bayer AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Product
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 02: Global Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 03: Global Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 04: Global Contraceptive Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 05: North America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 06: North America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 07: North America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 08: North America Contraceptive Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 09: U.S. Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 10: Canada Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 11: Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 12: Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 13: Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, by Country / Sub-region, 2021-2034
  • Table 15: Germany Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 16: U.K. Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 17: France Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 18: Italy Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 19: Spain Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 20: Scandinavia Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 21: Rest of Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 22: Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 24: Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 26: India Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 27: China Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 28: Japan Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 29: Australia Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 30: Southeast Asia Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 31: Rest of Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 32: Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 33: Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 34: Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 36: Brazil Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 37: Mexico Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 38: Rest of Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 39: Middle East & Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 40: Middle East & Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 41: Middle East & Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East and Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 43: GCC Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 44: South Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 45: Rest of Middle East and Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034

List of Figures

  • Figure 01: Global Contraceptive Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Contraceptive Drugs Market Revenue Share (%), by Product, 2025 & 2034
  • Figure 03: Global Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025 & 2034
  • Figure 04: Global Contraceptive Drugs Market Revenue Share (%), by Region, 2025 & 2034
  • Figure 05: North America Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 06: North America Contraceptive Drugs Market Revenue Share (%), by Product, 2025
  • Figure 07: North America Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 08: North America Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025
  • Figure 09: North America Contraceptive Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 10: North America Contraceptive Drugs Market Value Share (%), by Country, 2025
  • Figure 11: Europe Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 12: Europe Contraceptive Drugs Market Value Share (%), by Product, 2025
  • Figure 13: Europe Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: Europe Contraceptive Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: Europe Contraceptive Drugs Market Value (USD billion), by Country / Sub-region, 2025 & 2034
  • Figure 16: Europe Contraceptive Drugs Market Value Share (%), by Country / Sub-region, 2025
  • Figure 17: Asia Pacific Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 18: Asia Pacific Contraceptive Drugs Market Revenue Share (%), by Product, 2025
  • Figure 19: Asia Pacific Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: Asia Pacific Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025
  • Figure 21: Asia Pacific Contraceptive Drugs Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Contraceptive Drugs Market Revenue Share (%), by Country/Sub-region, 2025
  • Figure 23: Latin America Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 24: Latin America Contraceptive Drugs Market Revenue Share (%), by Product, 2025
  • Figure 25: Latin America Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 26: Latin America Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025
  • Figure 27: Latin America Contraceptive Drugs Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 28: Latin America Contraceptive Drugs Market Revenue Share (%), by Country/Sub-region, 2025
  • Figure 29: Middle East and Africa Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 30: Middle East and Africa Contraceptive Drugs Market Revenue Share (%), by Product, 2025
  • Figure 31: Middle East and Africa Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 32: Middle East and Africa Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025
  • Figure 33: Middle East and Africa Contraceptive Drugs Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 34: Middle East and Africa Contraceptive Drugs Market Revenue Share (%), by Country/Sub-region, 2025
  • Figure 35: Global Contraceptive Drugs Market Share (%), By Company, 2025